Nuveen Asset Management, LLC Revance Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

$329 Billion
Q1 2024

A detailed history of Nuveen Asset Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 352,042 shares of RVNC stock, worth $904,747. This represents 0.0% of its overall portfolio holdings.

Number of Shares

352,042

Previous 533,196 33.98%

Holding current value

$904,747

Previous $4.69 Million 63.04%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.65 - $9.31 $842,366 - $1.69 Million	-181,154 Reduced 33.98%	352,042 $1.73 Million
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $408,448 - $787,371	-70,301 Reduced 11.65%	533,196 $4.69 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $2.31 Million - $5.04 Million	201,103 Added 49.98%	603,497 $6.92 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $2,766 - $4,212	112 Added 0.03%	402,394 $10.2 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $1.81 Million - $3.48 Million	-98,565 Reduced 19.68%	402,282 $13 Million

Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $2.17 Million - $3.63 Million	-118,317 Reduced 19.11%	500,847 $9.25 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $3.73 Million - $7.4 Million	260,044 Added 72.41%	619,164 $16.7 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $134,795 - $238,700	-11,701 Reduced 3.16%	359,120 $4.96 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $35,979 - $59,122	-2,911 Reduced 0.78%	370,821 $7.07 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $136,212 - $304,674	-10,932 Reduced 2.84%	373,732 $6.1 Million
Q3 2021 Nov 12, 2021	SELL	$25.78 - $33.21 $4.55 Million - $5.86 Million	-176,430 Reduced 31.44%	384,664 $10.7 Million
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $2.81 Million - $3.34 Million	104,771 Added 22.96%	561,094 $16.6 Million
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $476,418 - $594,185	-19,826 Reduced 4.16%	456,323 $12.8 Million
Q4 2020 May 17, 2021	SELL	$23.41 - $28.34 $334,084 - $404,440	-14,271 Reduced 2.91%	476,149 $13.5 Million
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $1.51 Million - $1.83 Million	64,399 Added 15.12%	490,420 $13.9 Million
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $584,582 - $863,159	25,165 Added 6.28%	426,021 $10.7 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $625,035 - $1.32 Million	49,606 Added 14.12%	400,856 $9.79 Million
Q1 2020 May 14, 2020	BUY	$12.46 - $27.81 $305,693 - $682,290	24,534 Added 7.51%	351,250 $5.2 Million
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $225,551 - $389,781	19,344 Added 6.29%	326,716 $5.3 Million
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $1.06 Million - $1.51 Million	104,035 Added 51.16%	307,372 $4 Million
Q2 2019 Aug 15, 2019	BUY	$10.67 - $15.49 $2.17 Million - $3.15 Million	203,337 New	203,337 $2.64 Million

Others Institutions Holding RVNC

# of Institutions

214

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Revance Therapeutics, Inc. Transaction History